- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
Patent holdings for IPC class C07K 16/12
Total number of patents in this class: 2307
10-year publication summary
|
194
|
203
|
183
|
185
|
168
|
133
|
131
|
139
|
113
|
34
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Glaxosmithkline Biologicals S.A. | 1602 |
37 |
| MedImmune, LLC | 496 |
34 |
| The Regents of the University of California | 20902 |
33 |
| Regeneron Pharmaceuticals, Inc. | 4810 |
31 |
| Kymab Limited | 281 |
30 |
| Research Institute at Nationwide Children's Hospital | 646 |
30 |
| New York University | 1853 |
26 |
| Pfizer Inc. | 3418 |
23 |
| The University of Chicago | 1505 |
22 |
| National Research Council of Canada | 1555 |
21 |
| Valneva Austria GmbH | 119 |
20 |
| Wyeth LLC | 601 |
18 |
| University of Massachusetts | 2341 |
18 |
| Humabs Biomed SA | 120 |
17 |
| Institut Pasteur | 778 |
15 |
| Dnae Group Holdings Limited | 67 |
14 |
| Merus N.V. | 180 |
14 |
| Novartis AG | 10169 |
13 |
| Janssen Pharmaceuticals, Inc. | 430 |
13 |
| Arsanis Biosciences GmbH | 14 |
13 |
| Other owners | 1865 |